Literature DB >> 23076410

[No advantage for the overall group of breast cancer patients undergoing adjuvant therapy with zoledronic acid].

R Souchon1.   

Abstract

Entities:  

Year:  2012        PMID： 23076410     DOI： 10.1007/s00066-012-0252-7

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  3 in total

1.  Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial.

Authors:  Rebecca Aft; Michael Naughton; Kathryn Trinkaus; Mark Watson; Lourdes Ylagan; Mariana Chavez-MacGregor; Jing Zhai; Sacha Kuo; William Shannon; Kathryn Diemer; Virginia Herrmann; Jill Dietz; Amjad Ali; Matthew Ellis; Peter Weiss; Timothy Eberlein; Cynthia Ma; Paula M Fracasso; Imran Zoberi; Marie Taylor; William Gillanders; Timothy Pluard; Joanne Mortimer; Katherine Weilbaecher
Journal:  Lancet Oncol       Date:  2010-03-31       Impact factor: 41.316

Review 2.  The efficacy of zoledronic acid in breast cancer adjuvant therapy: a meta-analysis of randomised controlled trials.

Authors:  Tingting Yan; Wenjin Yin; Qiong Zhou; Liheng Zhou; Yiwei Jiang; Yueyao Du; Zhimin Shao; Jinsong Lu
Journal:  Eur J Cancer       Date:  2011-11-17       Impact factor: 9.162

3.  Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction.

Authors:  H L Neville-Webbe; R E Coleman; I Holen
Journal:  Br J Cancer       Date:  2010-02-16       Impact factor: 7.640
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.